Lyon, France – May 17, 2022 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a preclinical evaluation combining …
Author Archives: osivax
Are more powerful vaccines coming? Shots targeting T cells show promise.
Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology
Data also discussed in context of OVX836 clinical development update presentation at 2022 World Vaccine Congress Lyon, France – April 21, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today that the Phase 2a results for its broad-spectrum influenza vaccine candidate, OVX836, have been published under the title “Randomized, …
Osivax Appoints Dr. Michael Watson, Former President of Moderna Vaccine Division, to its Board of Directors
Company also announces upcoming presentation of clinical data for its pan-influenza vaccine candidate at World Vaccine Congress Lyon, France – April 14, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today the appointment of Dr. Michael Watson to its Board of Directors. Dr. Watson brings over 20 years …
World Congress Vaccine Washington
Washington DC – PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccin for broad-protection against multiple influenza strains”.
Covid-19 : à la recherche des vaccins de nouvelle génération
14 drug discovery startups to watch, according to top VCs
Vaccine Summit Boston 2022
Virtual – PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, a next generation universal Influenza vaccine focusing on T-Cell responses: Update on the clinical development plan”.
8th ESWI 2021
Virtual – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present additional efficacy endpoints of OVX836 as part of a poster entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”.
